The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC.
 
Matthew Lee
No Relationships to Disclose
 
Emily Miao
No Relationships to Disclose
 
Chenxin Zhang
No Relationships to Disclose
 
Xiaonan Xue
No Relationships to Disclose
 
Steven Tuckman
No Relationships to Disclose
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Merck; Novartis; Pfizer; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Haiying Cheng
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - Roche/Genentech; Spectrum Pharmaceuticals; Vaccinex